Early Methylene Blue for Mortality Reduction in High-Dose VasoPREssor-Dependent Septic Shock (EMPRESS): protocol for a multicenter randomized controlled trial

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a clinical study.

Septic shock remains one of the most lethal emergency and critical care conditions, with underlying pathophysiology closely linked to uncontrolled vasodilation mediated by nitric oxide activation of the soluble guanylate cyclase pathway (NO-sGC-cGMP pathway).

Who Took Part

The abstract describes 566 patients taking part.

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

The patients were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

Nothing was hidden in this open-label Methylene blue (non-peptide stack partner) study: the patients and staff both knew the treatment.

More than one site took part, so the patients came from several places.

Randomization will be stratified by baseline SOFA-1 score and study center.

The primary endpoint is 28-day all-cause mortality.

What Was Measured

Topics PubMed links to this paper include Methylene Blue, Shock, Septic, Randomized Controlled Trials as Topic, Vasoconstrictor Agents, China and Enzyme Inhibitors.

Author keywords: Mortality, Septic shock and Vasopressor.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Methylene blue (non-peptide stack partner) in 566 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 1 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Scandinavian journal of trauma, resuscitation and emergency medicine), a journal based in England.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.